The clinical data of 14 patients with neuroendocrine tumors who received Peptide Receptor Radionuclide Therapy (PRRT) from December 2018 to May 2021 were retrospectively analyzed. Among them, 2 patients demonstrated proprogressive disease, 2 patients had partial response, and 10 patients had stable disease. Grade 1-2 myelosuppression occurred in 5 patients. and 1 patient became grade 3 myelosuppression，which recovered to grade 2 after symptomatic treatment. No grade 2 or higher treatment-related renal toxicity was observed in any of the patients. PRRT is efficacy and no significant side effects for unresectable metastatic neuroendocrine tumors.
回顾性分析2018年12月至2021年5月接受肽受体放射性核素治疗（PRRT）的14例神经内分泌肿瘤患者资料，其中2例疾病进展，2例部分缓解，10例病情稳定。5例出现1~2级骨髓抑制，1例出现3级骨髓抑制，经对症治疗后恢复至2级。所有患者均未发现2级以上治疗相关性肾脏毒性。PRRT对于无法手术切除的转移性神经内分泌肿瘤有较好疗效，无明显不良反应。.